MARKET

MANE

MANE

VERADERMICS INC
NYSE
125.00
+1.42
+1.15%
Opening 12:29 06/30 EDT
OPEN
122.16
PREV CLOSE
123.58
HIGH
125.63
LOW
120.52
VOLUME
193.26K
TURNOVER
--
52 WEEK HIGH
128.24
52 WEEK LOW
32.00
MARKET CAP
5.22B
P/E (TTM)
-58.7986
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MANE last week (0622-0626)?
Weekly Report · 1d ago
Veradermics, Incorporated (MANE) Receives a Buy from Citi
TipRanks · 06/22 10:57
Weekly Report: what happened at MANE last week (0615-0619)?
Weekly Report · 06/22 10:45
Analysts’ Top NA Picks: Newron Pharmaceuticals SpA (NWPHF), Veradermics, Incorporated (MANE)
TipRanks · 06/22 10:44
Veradermics Price Target Announced at $135.00/Share by LifeSci Capital
Dow Jones · 06/16 17:01
LifeSci Capital Initiates Coverage On Veradermics with Outperform Rating, Announces Price Target of $135
Benzinga · 06/16 16:51
Analysts Offer Insights on NA Companies: Sunbelt Rentals Holdings Inc (SUNB), Veradermics, Incorporated (MANE) and JBS (JBS)
TipRanks · 06/16 13:02
Veradermics, Incorporated (MANE) Receives a Buy from Jefferies
TipRanks · 06/16 13:00
More
About MANE
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

Webull offers Veradermics Inc stock information, including NYSE: MANE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MANE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MANE stock methods without spending real money on the virtual paper trading platform.